ALX Oncology’s (ALXO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of ALX Oncology (NASDAQ:ALXO) in a research note published on Thursday, Benzinga reports. They currently have a $25.00 price objective on the stock.

Separately, Cantor Fitzgerald reiterated an overweight rating on shares of ALX Oncology in a report on Wednesday, May 29th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $18.17.

ALX Oncology Trading Down 6.6 %

Shares of NASDAQ:ALXO opened at $2.67 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.21 and a quick ratio of 5.21. The company’s 50-day moving average price is $7.25 and its two-hundred day moving average price is $11.81. The stock has a market capitalization of $139.11 million, a PE ratio of -0.77 and a beta of 1.06. ALX Oncology has a one year low of $2.50 and a one year high of $17.83.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.16. On average, equities analysts forecast that ALX Oncology will post -2.89 EPS for the current fiscal year.

Insider Transactions at ALX Oncology

In other ALX Oncology news, insider Sophia Randolph sold 12,000 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $15.94, for a total transaction of $191,280.00. Following the completion of the sale, the insider now owns 330,349 shares of the company’s stock, valued at approximately $5,265,763.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Sophia Randolph sold 12,000 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the completion of the transaction, the insider now directly owns 330,349 shares in the company, valued at approximately $5,265,763.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $7.90, for a total transaction of $158,000.00. Following the sale, the insider now owns 593,447 shares of the company’s stock, valued at $4,688,231.30. The disclosure for this sale can be found here. Insiders have sold 58,469 shares of company stock valued at $554,946 in the last quarter. Insiders own 33.40% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

Large investors have recently added to or reduced their stakes in the company. EntryPoint Capital LLC purchased a new position in ALX Oncology during the first quarter valued at approximately $32,000. abrdn plc bought a new stake in shares of ALX Oncology during the fourth quarter valued at approximately $986,000. China Universal Asset Management Co. Ltd. raised its position in shares of ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after buying an additional 4,706 shares during the last quarter. Swiss National Bank bought a new stake in shares of ALX Oncology during the first quarter valued at approximately $493,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of ALX Oncology during the fourth quarter valued at approximately $28,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.